XanaMIA Part A trial achieves target enrolment
Filed with ASX · · 2 pages · English
Sydney 29 November 2021. Actinogen Medical ASX:ACW (“ACW” or “the Company”) is pleased to announce that target enrolment has been reached in the XanaMIA Part A trial of 105 participants and that results are expected in Q2 CY2022. The Part A XanaMIA trial is assessing the efficacy of 5mg and 10mg Xanamem doses compared to placebo in older healthy patients (aged 50 to 80 years old), over six weeks,
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Strategic Update & Capital Raising Investor Presentation
- Program Expansion & Capital Raising
- ACW announces open IND for Phase 2 Fragile X trial & LOI
- R&D Tax Incentive Rebate received of A$1.435 million
- Actinogen Medical FY21 Results- Progressing the Pipeline
Later from Actinogen Medical
- ACW Strategic Collaboration with Oxford Uni Researchers
- Capital Raising Completion
- Actinogen Medical: ACW CEO Presents at San Francisco Healthcare Conference
- Actinogen appoints XanaFX Phase 2 trial manager
- Actinogen XanaMIA Part A trial results expected in April
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical